A precise and non-toxic treatment that targets lung cancer cells at the nanoscale is able to effectively kill the cells even at a low dose.
Researchers from Washington State University and the Department of Energy’s Pacific Northwest National Laboratory (PNNL) used tiny tubes made from organic molecules called peptoids to deliver cancer-killing drugs in a targeted manner. The research, led by Yuehe Lin, professor in WSU’s School of Mechanical and Materials Engineering, and Chun-Long Chen, a senior research scientist at PNNL and a joint faculty fellow at the University of Washington, was published as the cover story in the prestigious journal Small.
The biologically-inspired nanotubes, which are about a hundred thousand times thinner than a human hair, were rolled up from membrane-like nanosheets. The drug molecules, fluorescent dyes and cancer-targeting molecules were precisely placed within the nanotubes, enabling them to track the efficiency of drug delivery into the cancer cells.
The new technology allows the two drugs – one for chemotherapy and the other for a less-invasive photodynamic therapy treatment – to be delivered directly to the cancer cells. Photodynamic therapy uses a chemical that, when exposed to light, releases reactive oxygen species (ROS) that kill cancer cells. The researchers’ dual-drug approach enabled the use of a lower dose of the cancer drugs than using a single drug, leading to effective killing of cancer cells with low toxicity.
“By precisely engineering these nanotubes with fluorescent dyes and cancer targeting molecules, scientists can clearly locate tumor cells and track how the drug regimen is performing,” said Lin. “We can also track how nanotubes enter and deliver the drugs inside the cancer cell.”
The team tested the nanotubes on lung cancer cells and found that they delivered the chemotherapy drug doxorubicin directly into the fast-dividing cancer cells, resulting in highly efficient cancer killing while using less chemotherapy drugs.
“This is a promising approach for precision targeting with little damage to healthy surrounding cells,” said Lin.
While other nanomaterials, such as carbon nanotubes, have been used to deliver and track cancer-killing drugs, researchers have found that they are toxic to the body. Furthermore, they didn’t do well at precisely recognizing molecules.
“By using these peptoids, we were able to develop highly programmable nanotubes and a biocompatible delivery mechanism,” said Chen. “We also harnessed the high stability of peptoid and its well-controlled packing to develop nanotubes that are highly stable.”
“Due to their unique structure, these nanotubes can be easily assembled for use in cancer therapy and stay in the body longer for treatment,” said Lin.
The team is now looking for collaboration and funding opportunities with pharmaceutical companies to extend the research into animal and clinical studies.
The Latest on: Lung cancer
via Google News
The Latest on: Lung cancer
- Lung Cancer Research Foundation Announces New Research Collaboration with AstraZenecaon February 23, 2021 at 10:10 am
The Lung Cancer Research Foundation (LCRF) today announced a collaboration with AstraZeneca to fund over $900,000 in research grants focused on understanding resistance to epidermal growth factor ...
- New Study Seeks Origins of Young Lung Canceron February 23, 2021 at 8:50 am
Addario Lung Cancer Medical Institute and GO2 Foundation for Lung Cancer to learn about environmental, lifestyle, and demographic risks of developing lung cancer under the age of 40.
- Actor's death shows lung cancer can strike non-smokerson February 23, 2021 at 8:05 am
Lung cancer is by far the most common cause of cancer death in the U.S., with approximately 154,000 Americans succumbing annually to the disease. This accounts for 25 percent of all cancer death in ...
- Rush Limbaugh's Widow Speaks Out After He Died of Lung Canceron February 23, 2021 at 7:57 am
Kathryn Limbaugh spoke to listeners of The Rush Limbaugh Show for two hours on Monday, days after Rush Limbaugh died of cancer ...
- Sanofi, Regeneron's Libtayo snags lung cancer nod, taking a stab at Keytruda's megablockbuster leadon February 23, 2021 at 7:08 am
Sanofi and Regeneron’s immuno-oncology med Libtayo is on a roll with its second FDA approval in just two weeks. The latest nod pushes the PD-1 inhibitor out of its skin cancer comfort zone and into ...
- Cancer Death Rates Continue to Fall in Europe, Except For...on February 23, 2021 at 6:34 am
Cancer death rates overall continue to fall in the EU, with the exception of pancreatic cancer in both sexes and lung cancer among women.
- Regeneron wins FDA OK in lung cancer for immunotherapy rival to Merck's Keytrudaon February 22, 2021 at 3:39 pm
The approval of Libtayo in first-line lung cancer will pit Regeneron's drug, developed in partnership with Sanofi, against Merck's top-selling immunotherapy Keytruda.
- FDA Approves Libtayo as Monotherapy for Advanced Non-Small Cell Lung Canceron February 22, 2021 at 12:04 pm
This is the third approval for Libtayo, following approvals as the first immunotherapy for patients with advanced basal cell carcinoma and as the first systemic treatment for advanced cutaneous ...
- Live politics updates: Biden visits friend Bob Dole who just announced lung cancer diagnosison February 21, 2021 at 9:31 am
The White House told reporters he was visiting "his close friend" Dole, with whom Biden served in the Senate for more than two decades.
- The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung canceron February 20, 2021 at 3:54 pm
In multiple primary lung adenocarcinomas, there is a high proportion of patients harboring EGFR mutations, and most lesions present as multiple ground-glass opacity (GGO) in imaging examinations. 2 ...
via Bing News